New drug combos tested for Tough-to-Treat skin cancer
NCT ID NCT04417621
Summary
This study is testing several combinations of an experimental drug called LXH254 with other cancer medications for people with advanced melanoma that has spread and hasn't responded to previous treatments. The research aims to see if these combinations can shrink tumors and control the cancer's growth while monitoring side effects. It's for adults and adolescents (12+) with specific genetic changes in their cancer who have already tried standard immunotherapies or targeted drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Florida Cancer Specialists
Fort Myers, Florida, 33901, United States
-
H Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic Mayo Rochester
Rochester, Minnesota, 55905, United States
-
Mayo Clinic Rochester
Rochester, Minnesota, 55905, United States
-
Memorial Sloan Kettering
New York, New York, 10017, United States
-
NYU Laura and Isaac Perlmutter Cancer Center
New York, New York, 10016, United States
-
Novartis Investigative Site
CABA, Buenos Aires, C1426ANZ, Argentina
-
Novartis Investigative Site
North Sydney, New South Wales, 2060, Australia
-
Novartis Investigative Site
Wooloongabba, Queensland, 4102, Australia
-
Novartis Investigative Site
Subiaco, Western Australia, 6008, Australia
-
Novartis Investigative Site
Leuven, 3000, Belgium
-
Novartis Investigative Site
Wilrijk, 2610, Belgium
-
Novartis Investigative Site
Lille, 59037, France
-
Novartis Investigative Site
Marseille, 13885, France
-
Novartis Investigative Site
Paris, 75475, France
-
Novartis Investigative Site
Pierre-Bénite, 69495, France
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Villejuif, 94800, France
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Essen, 45147, Germany
-
Novartis Investigative Site
Heidelberg, 69120, Germany
-
Novartis Investigative Site
Tübingen, 72076, Germany
-
Novartis Investigative Site
Ramat Gan, 5265601, Israel
-
Novartis Investigative Site
Milan, MI, 20133, Italy
-
Novartis Investigative Site
Napoli, 80131, Italy
-
Novartis Investigative Site
Maastricht, Limburg, 6229 HX, Netherlands
-
Novartis Investigative Site
Oslo, 0310, Norway
-
Novartis Investigative Site
Lausanne, 1011, Switzerland
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Manchester, M20 2BX, United Kingdom
-
The Angeles Clinic and Research Institute
Los Angeles, California, 90025, United States
-
UCSF Medical Center
San Francisco, California, 94143, United States
-
Univ of TX MD Anderson Cancer Cntr
Houston, Texas, 77030, United States
-
University of Pittsburgh Med Center
Pittsburgh, Pennsylvania, 15213, United States
Conditions
Explore the condition pages connected to this study.